T-ALL is a hematologic malignancy^[@R5],[@R6],[@R7].^characterized by activating mutations in the *NOTCH1*^[@R8]^ gene and alterations in the *FBXW7*^[@R9]^ ligase resulting in activation of Notch signaling. Although the importance of NOTCH activation in T-ALL is well established, the detailed molecular mechanisms mediating NOTCH1-induced transformation remain unknown. We hypothesized that NOTCH1 interacts with epigenetic modulators to control gene expression. In addition, we proposed that genetic alterations in key components of the epigenetic machinery could amplify oncogenic signals. To test this notion, we analyzed an extensive series of array comparative genomic hybridization (aCGH) data on adult T-ALL primary samples for the presence of recurrent deletions encompassing genes involved in epigenetic regulation. This analysis revealed the presence of recurrent deletions involving genes encoding core components of the Polycomb Repressive Complex 2 (PRC2). This complex is the "writer" of a major repressive chromatin modification, Lysine 27 trimethylation on Histone 3 (H3K27me3). We found recurrent deletions encompassing the *EZH2*^[@R10]--[@R12]^ and *SUZ12*^[@R13],[@R14]^ loci ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Following these results we screened primary tumor DNA samples for the presence of somatic mutations affecting the core components of the PRC2 complex^[@R15]^. This analysis revealed the presence of truncating or missense mutations in both *EZH2* (11/68) and *SUZ12* (3/68). *EZH2* mutations included four non-synonymous single-nucleotide substitutions, one nonsense mutation and six frameshift-creating insertions and deletions ([Fig. 1a,b](#F1){ref-type="fig"}, [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). *SUZ12* mutations identified in T-ALL included 2 missense and 1 frameshift mutation ([Fig. 1c,d](#F1){ref-type="fig"}). *Loss of function* mutations and deletions in *EZH2* have been previously associated with myeloid leukemias^[@R10]--[@R12]^. In contrast, *gain of function* EZH2 mutations involved in B-cell lymphomas are typically single amino acid substitutions involving Y641^[@R16],[@R17]^. Nonsense and frameshift mutations in *EZH2* and *SUZ12* in T-ALL are protototypical *loss of function* truncating alleles consistent with a PRC2 tumor suppressor role for these genes in T-cell transformation. Notably, 7 *EZH2* and 3 *SUZ12* mutations were heterozygous but also 4 out of 11 EZH2 and 1 out 3 *SUZ12* mutations were homozygous^[@R18]^. In all 8/14 cases (6 *EZH2* and 2 *SUZ12* variants) with available matched bone marrow remission genomic DNA we confirmed the somatic origin of the *EZH2* and *SUZ12* mutations ([Fig. 1a,c](#F1){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The convergent findings of our re-sequencing effort and copy number analysis thus identified *EZH2* and *SUZ12* as novel tumor suppressor genes mutated and deleted in T-ALL. Overall, genetic lesions targeting *EZH2* or *SUZ12* were identified in 17/68 (25%) of primary T-ALL samples ([Fig. 1e](#F1){ref-type="fig"}). The complete absence of EZH2 protein in both cases with combined deletion and mutation of the *EZH2* gene examined ([Fig. 1f](#F1){ref-type="fig"}) revealed that these *loss of function* mutations and suggested that inactivation of the PRC2 complex may constitute an important pathogenetic event in human T-ALL. Further targeted re-sequencing revealed that PRC2 genetic alterations were frequently (in 65% of the cases) associated with oncogenic *NOTCH1* mutations ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). This frequency suggested that the two events could directly or indirectly co-operate. We analyzed the effects of PRC2 inactivation in the expression of prototypical NOTCH1 target genes such as *HES1* and *DTX1* in T-ALL cell lines harboring *NOTCH1* mutations^[@R9],[@R19]^. These experiments showed that silencing of both EZH2 and SUZ12 resulted in transcriptional upregulation of both target genes ([Fig. 1g](#F1){ref-type="fig"}, [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"} and not shown), suggesting that loss of PRC2 could potentiate the NOTCH1 transcriptional program.

To further explore the role of the PRC2 complex in Notch target expression and T-ALL induction/progression we aimed to dissect the epigenetic changes associated with transformation in T-ALL. Chromatin ImmunoPrecipitation (ChIP) studies using CUTLL1 cells^[@R15]^, a human T-ALL line^[@R20]^ characterized by a Notch1 translocation showed that NOTCH1 binding on the promoter of *HES1*, a canonical NOTCH1 target required for NOTCH1-induced transformation^[@R5],[@R21]^ ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}), peaks at −50 to −100 bp relative to the Transcriptional Start Site (TSS) followed by enrichment of RNA Polymerase II (POL II) ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). No binding for NOTCH1 or POL II was observed in a NOTCH1-negative T-ALL cell line ([Supplementary Fig. 3b,c](#SD1){ref-type="supplementary-material"}). Inhibition of the Notch1 signaling using a γ-secretase inhibitor (γSI)^[@R20]^ ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}) abrogated NOTCH1 binding on the *HES1* promoter and led to decreased levels of *HES1* mRNA expression ([Supplementary Fig. 4b,c](#SD1){ref-type="supplementary-material"}). Subsequent γSI removal restored high levels of NOTCH1, POL II and the activating mark acetylation of Lysine 9 of Histone 3 (H3K9ac) on the *HES1* promoter as well as *HES1* expression ([Supplementary Fig. 4b--e](#SD1){ref-type="supplementary-material"}).

To further test the interplay between activation of NOTCH1 and epigenetic regulation we used a Notch1-IC-induced T-ALL animal model^[@R22]^, which recapitulates most of the features of human T-ALL ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 5a-c](#SD1){ref-type="supplementary-material"}). Most *Notch1*-induced leukemias show a double positive (DP) phenotype characterized by the expression of both CD4 and CD8 co-receptors ([Fig. 2b](#F2){ref-type="fig"}). To study the transcriptional and epigenetic changes in *Hes1* during Notch1 driven leukemogenesis we compared FACS-sorted DP Notch1-transformed cells (T-ALL) to normal DP thymocytes, which show low levels of Notch1 and *Hes1* activation ([Fig. 2b,c](#F2){ref-type="fig"}). Scanning of the murine *Hes1* promoter revealed significant enrichment for Notch1 binding in T-ALL compared to DP ([Fig. 2e](#F2){ref-type="fig"}) accompanied by enrichment of PolII on the TSS ([Fig. 2f](#F2){ref-type="fig"}). Moreover, ChIP experiments showed enrichment of the activating acetylation of lysine 9 on H3 (H3K9ac)^[@R23]^ and trimethylation of lysine 4 on H3 (H3K4me3)^[@R24]^ ([Fig. 2g,h](#F2){ref-type="fig"}) around the *Hes1* TSS, followed by enrichment for the transcriptional elongation-associated form of Pol II (Serine 2-Phosphorylated Pol II, S2-P-Pol II) and trimethylation of lysine 36 on histone 3 (H3K36me3) on the gene body ([Fig. 2i](#F2){ref-type="fig"}). One of the most prominent differences, however, was the loss of the repressive H3K27me3 from the *Hes1* promoter in the leukemic cells that was accompanied by gain of acetylation of the same residue ([Fig. 2j](#F2){ref-type="fig"}), an activating epigenetic mark^[@R25]^. Similar results were obtained for *Deltex1* (*Dtx1),* which is also a direct Notch1 target gene ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}), but not on the *Gapdh* locus, used as a control. These results demonstrated that Notch1-mediated oncogenic transformation was coupled to epigenetic changes, including the loss of the H3K27me3 histone mark from Notch target gene promoters.

To test whether the Hes1 behavior is part of a wider Notch1 driven epigenetic reprogramming in leukemic cells, we performed whole transcriptome profiling ([Supplementary Tables 3,4](#SD1){ref-type="supplementary-material"}) and ChIP-Sequencing (ChIP-Seq, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}) for H3K4me3, H3K9ac and H3K27me3 ([Fig. 3a,b](#F3){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). Computational validation of Chip-Seq results showed high correlation of the biological replicates ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}) and consistency with gene expression ([Supplementary Fig. 8,9](#SD1){ref-type="supplementary-material"}). Enrichment analyses ([Supplementary Tables 6--9](#SD1){ref-type="supplementary-material"}) revealed that the regulated (and marked by modifications) genes belong in functional categories related to normal T cell differentiation and T cell transformation ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). Genes up-regulated in Notch1-driven leukemic cells compared to normal DP thymocytes were primarily characterized by loss of H3K27me3 (*P= 6.91x10^−22^*). Unexpectedly, gain of H3K9ac in these genes was much less significant (*P=1.52x10^−4^*) ([Fig. 3a,b](#F3){ref-type="fig"} and [Supplementary Tables 10,11](#SD1){ref-type="supplementary-material"}), suggesting that loss of H3K27me3 is the most prominent epigenetic change coupled to gene activation. This in turn, provided evidence for a central role of PRC2 in T-ALL. On the contrary, down-regulated genes showed primarily loss of H3K9ac (*P=2.79x10^−19^*, [Supplementary Tables 11,12](#SD1){ref-type="supplementary-material"}). Most notably, the loss of H3K27me3 from the TSS region of T-ALL up-regulated transcripts was not due to lower total levels of the H3K27me3 in T-ALL ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"} and [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Changes in H3K4me3 seemed to have a lesser role related to context-dependent and fine-tuning regulation of gene expression ([Fig. 3a,b](#F3){ref-type="fig"} and [Supplementary Table 11](#SD1){ref-type="supplementary-material"}). Targets of Notch1, such as *Hes1*, *Dtx1, Pre-TCR alpha (Ptcra)* and *c-Myc,* exhibited loss of H3K27me3, whereas the changes of H3K4me3 and H3K9ac were more subtle ([Fig. 3d](#F3){ref-type="fig"} and [Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}), suggesting a functional interaction between Notch1 and loss of H3K27me3, generally associated with decreased activity of the PRC2 complex.

To further explore the role of Notch1 in driving the loss of H3K27me3 we performed ChIP-Seq for Notch1 ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). Whereas no significant peaks were detected in DP, analysis of Notch1-transformed T-ALL lymphoblasts revealed a large number of direct Notch1 binding events. Importantly, H3K27me3 loss in T-ALL was broadly overlapping with direct Notch1 binding in TSS regions ([Fig. 4a,b](#F4){ref-type="fig"}). The lack of enrichment of H3K9ac gain or loss suggested that Notch1 binding is highly specific to H3K27me3 loss ([Fig. 4a](#F4){ref-type="fig"}). The observed loss of H3K27me3 in Notch1 targets is mainly localized in a narrow region around TSSs ([Fig. 4b](#F4){ref-type="fig"}). Loss of H3K27me3 was observed specifically on Notch1 targets and not in the whole T-ALL genome ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Figs 14 and 15](#SD1){ref-type="supplementary-material"}). These combined data suggested that significant loss of H3K27me3 is a hallmark of the oncogenic function of Notch1 in T-ALL.

The rapid increase of Notch1-IC levels in human T-ALL lines upon γSI removal ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}) resulted in a dynamic and rapid loss of the H3K27 ([Fig. 4c](#F4){ref-type="fig"} and [Supplementary Fig. 16](#SD1){ref-type="supplementary-material"}), further proving the inverse correlation of the two events. This led us to further investigate this relationship in additional human T-ALL cell lines and primary T-ALL samples. Initially we screened additional T-ALL lines (DND41 and CEM), exhibiting high N1-IC and *HES1* expression, and normal (*HES1^low^*) human thymocytes ([Fig. 4d](#F4){ref-type="fig"}). The levels of H3K27me3 were once more inversely correlated with *HES1* expression ([Fig. 4d](#F4){ref-type="fig"}). To exclude the possibility that these results were due to cell line artifacts, we studied primary samples whose high leukemogenic potential was evaluated using transplantation ([Fig. 4e](#F4){ref-type="fig"} and [Supplementary Fig. 17](#SD1){ref-type="supplementary-material"}). The primary T-ALL leukemic blasts exhibited higher levels of *HES1* compared to normal human thymocytes and the levels of H3K27me3 were inversely correlated with *HES1* expression ([Fig. 4f](#F4){ref-type="fig"}). These studies demonstrated that the correlation between oncogenic NOTCH1 binding and loss of H3K27me3 is a universal characteristic of T-ALL.

We then focused on the relationship between oncogenic NOTCH1 with the PRC2 complex. Initially, the analysis revealed that Notch1 binding sites are enriched for PRC2 targets (4.3-fold enrichment and *P=8.45x10^−110^*, [Supplementary Table 9](#SD1){ref-type="supplementary-material"}). Moreover, we analyzed the effects of Notch1 activation on the occupancy of Notch1 target genes by the EZH2 catalytic subunit of PRC2. These studies demonstrated that Notch1 binding led to significant Ezh2 eviction from the *Hes1* promoter ([Fig. 4g](#F4){ref-type="fig"}). This could not be attributed to lower EZH2 expression in the cancer cells ([Supplementary Fig. 18a](#SD1){ref-type="supplementary-material"}). ChIP analysis for SUZ12 binding yielded identical results ([Fig. 4h](#F4){ref-type="fig"}). EZH2 eviction and H3K27 loss was not only a feature of the Notch1-IC model utilized, as identical results were obtained using "weaker" human Notch1HD/PEST alleles in *in vivo* disease models ([Supplementary Fig. 19](#SD1){ref-type="supplementary-material"}). These epigenetic effects were observed even at the very early stages of the disease ([Supplementary Fig. 20](#SD1){ref-type="supplementary-material"}). Moreover, down-regulation of N1-IC levels byγSI treatment, led to a marked decrease of EZH2 binding on the *HES1* or *DTX1* promoters ([Supplementary Fig. 18](#SD1){ref-type="supplementary-material"}). Also, the binding of JARID2^[@R26],[@R27]^, one of the recruiters of the PRC2 complex to DNA, on the *HES1* promoter was also inversely correlated to Notch1 binding ([Fig. 4i](#F4){ref-type="fig"}). These responses were rapid, as significant changes in Notch1 binding and PRC2 recruitment were detected as early as 30min upon γSI removal ([Supplementary Fig. 21](#SD1){ref-type="supplementary-material"}). The reverse correlation between Notch1-PRC2 binding and H3K27me3 levels was found in all T-ALL lines studied ([Supplementary Fig. 22](#SD1){ref-type="supplementary-material"}). Identical epigenetic changes were also noted when the Notch pathway was inhibited using a dominant negative form of MAML1 ([Supplementary Fig. 23](#SD1){ref-type="supplementary-material"}).

The presented mechanistic interaction between NOTCH1 and the PRC2 complex suggested a potential role for PRC2 mutations in NOTCH-induced transformation, although Notch-independent effects are also possible. To start addressing pathway interaction, we used a *Drosophila* Notch-driven tumor model^[@R28]^ to evaluate the impact of knockdown of *E(z*) in cells that express weak activating alleles of Notch ([Supplementary Fig. 24](#SD1){ref-type="supplementary-material"}). We were able to show that the combination of Notch activation and *E(z*) loss resulted in eye tumor overgrowth^[@R28],[@R29]^ in approximately 50% of the progeny (*n= 64*)^[@R30]^. In agreement with such a notion of cooperation between Notch and PRC2 loss we were able to show that: EZH2 silencing resulted in decreased apoptosis triggered by γSI inhibition of Notch signaling in human T-ALL lines ([Supplementary Fig. 25](#SD1){ref-type="supplementary-material"}). Moreover, EZH2 silencing increased the *in vivo* tumorigenic potential of T-ALL cells and led to enhanced mortality in transplantation experiments ([Supplementary Fig. 26](#SD1){ref-type="supplementary-material"}). These studies suggested a striking conservation of the Notch:PRC2 pathway interaction in tumorigenesis and further established the role of the PRC2 complex as a tumor suppressor in T-ALL, although the exact mechanisms of function have to be detailed further. We believe that our studies offer new therapeutic avenues for the treatment of T cell leukemia^[@R31],[@R32]^ as inhibitors of H3K27 demethylases^[@R33]^, alone or in combination with targeted anti-Notch1 therapies, could antagonize oncogenic Notch1 function and be further exploited for the treatment of T-ALL.
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![The PRC2 complex as a tumor suppressor in T-ALL. (**a**) Structure of the EZH2 protein including 2 SANT DNA binding domains, the cysteine-rich CXC domain and the catalytic SET domain. Overview of all *EZH2* mutations identified in primary T-ALL samples. Filled circles: nonsense and frameshift mutations, open circles: missense mutations. (**b**) Representative chromatograms of paired diagnosis and remission genomic DNA samples showing somatic mutations in exon 8 and exon 10 of *EZH2*. (**c**) Structure of the SUZ12 protein including a zinc finger domain and the VEFS domain. (**d**) Representative DNA sequencing chromatograms showing a frame-shift mutation in exon 10 of *SUZ12* and of paired diagnosis and remission genomic DNA samples showing a somatic point mutation in exon 14 of this gene. (**e**) Pie-chart summarizing the frequencies of homozygous and heterozygous mutations of *EZH2* and *SUZ12* in adult TALL patients. (**f**) EZH2 protein levels in samples from patients (\#1 and \#4) with mutations and deletions on the *EZH2* gene compared to WT controls. (**g**) Silencing of EZH2 and SUZ12 in the Jurkat human T-ALL line. HES1 and DTX1 mRNA expression levels followed silencing of either SUZ12 or EZH2. Knockdown of the luciferase (*LUC*) gene was used as a control.](nihms345806f1){#F1}

![Notch1-induced epigenetic changes in an *in-vivo* model of T-ALL. (**a**) Comparison of the size of the thymus in leukemic animals and control littermates. (**b**) Cell populations used in this study. (**c**) Western blot showing the expression of N1-IC in DP and T-ALL cells. (**d**) Hes1 cDNA levels between DP and T-ALL. (**e, f**) ChIP of Notch1 and Pol II on the *Hes1* promoter in the indicated cell populations. (**g-j**) ChIP of the indicated histone marks and S2-P-Pol II in DP and T-ALL cells.](nihms345806f2){#F2}

![Characterization of T-ALL epigenetic landscape using ChIP-Seq for H3K9ac, H3K4me3 and H3K27me3. (**a**) Cluster of the major gene expression changes between T-ALL and DP and the accompanied epigenetic changes. Left part: Expression heatmap representing up (red)- and down (blue)-regulated genes with significant epigenetic changes. Right panel: Heatmap representation of the epigenetic marks in T-ALL and DP in TSSs of selected genes. "+":gain and "−":loss in the levels of epigenetic mark in T-ALL versus DP. Loss of H3K27me3 (*P=6.91x10^−22^*, blue bar) and gain of H3K9ac (*P=1.52x10^−4^*, green bar) are enriched in up-regulated genes, whereas loss of H3K9ac (*P=2.79x10^−19^*, red bar) is enriched in down-regulated genes. (**b**) Bar graphs indicate the percentage of genes characterized by each modification in T-ALL cells. The plus and minus signs are used as above. Pink and blue frames: prevalent epigenetic clusters in down-regulated and up-regulated genes, respectively. (**c**) Functional annotation of epigenetic changes (T-ALL vs DP) in H3K9ac (yellow bars) and H3K4me3 (gray bars) shows enrichment in specific biological processes. (**d**) ChIP-Seq results for two well-characterized Notch1 targets, *Hes1* and *Dtx1* (arrows denote the TSS).](nihms345806f3){#F3}

![Notch1 binding mediates loss of H3K27me3 and eviction of PRC2 in T-ALL. (**a**) Enrichment of Notch1 binding sites around TSSs characterized by each indicated histone mark. (**b**) H3K27me3 average signal profiles around TSS areas (blue line: Notch1-bound genes, gray line: genes not-bound by Notch1). (**c**) ChIP for H3K27me3 in a T-ALL cell line (CUTLL1) treated with γSI. The Loucy T-ALL line is used as a negative control. (**d**) *HES1* expression in the indicated cell lines and normal human thymocytes and ChIP for H3K27me3 in the indicated cell lines and primary cells. (**e**) High leukemogenic potential of the human T-ALL samples in xenograft models. Spleen sections of recipient mice stained with an hCD45 antibody or an IgG control. (**f**) qPCR for *HES1* expression and the levels of H3K27me3 in primary human T-ALL samples and human thymocytes (*P\<0.0001* between M69 and the human thymus). (**g**) ChIP experiments for Ezh2 on the *Hes1* promoter in DP (green) and T-ALL (red). (**h**) Suz12 binding on the *Hes1* promoter. (**i**)γSI-mediated changes of the N1-IC levels modulate JARID2 recruitment to the *HES1* promoter (*P=0.059*).](nihms345806f4){#F4}
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